Trials / Completed
CompletedNCT00291668
Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease
A Phase II, Multi-center, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Assess the Safety and Efficacy of CDP870/Certolizumab Pegol, Dosed Subcutaneously in Patients With Active Crohn's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 94 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 16 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-centre, randomized, double-blind, dose response clinical study of CDP870 in patients with Crohn's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Certolizumab Pegol | * Active Substance: Certolizumab Pegol * Pharmaceutical Form: Solution for injection in pre-filled syringe * Concentration: 200 mg/mL * Route of Administration: Subcutaneous use |
| OTHER | Placebo | * Active Substance: isotonic sodium chloride solution * Pharmaceutical Form: Solution for injection * Concentration: 1 mL * Route of Administration: Subcutaneous use |
Timeline
- Start date
- 2006-03-02
- Primary completion
- 2007-11-08
- Completion
- 2007-11-08
- First posted
- 2006-02-14
- Last updated
- 2020-08-03
- Results posted
- 2020-08-03
Locations
22 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00291668. Inclusion in this directory is not an endorsement.